$ELDN
Eledon Pharmaceuticals, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020040128 Filed on August 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.270M $1.790M $1.890M
YoY Change -29.05% -3.76% 11.18%
% of Gross Profit
Research & Development $830.0K $2.297M $2.990M
YoY Change -63.87% 72.84% 171.82%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $2.100M $4.089M $4.880M
YoY Change -48.64% 28.22% 74.6%
Operating Profit -$4.089M
YoY Change 28.22%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.00K -$4.000K -$6.000K
YoY Change -350.0% -45.45%
Pretax Income -$2.590M -$4.090M -$4.880M
YoY Change -36.67% 28.21% 73.67%
Income Tax
% Of Pretax Income
Net Earnings -$2.586M -$4.093M -$4.881M
YoY Change -36.82% 28.35% 73.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.755M -$6.292M -$9.385M
COMMON SHARES
Basic Shares Outstanding 9.434M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.800M $13.70M $9.100M
YoY Change -35.77% -28.65% -59.56%
Cash & Equivalents $8.764M $13.70M $13.70M
Short-Term Investments
Other Short-Term Assets $83.00K $78.00K $27.00K
YoY Change 6.41% 420.0% 58.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.800M $15.18M $10.32M
YoY Change -35.45% -27.98% -57.0%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $10.00K $12.00K
YoY Change 1900.0% -50.0%
Goodwill $1.867M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $755.0K $800.0K
YoY Change -33.77%
Total Long-Term Assets $700.0K $3.035M $3.179M
YoY Change -76.94% 60.84% 67.32%
TOTAL ASSETS
Total Short-Term Assets $9.800M $15.18M $10.32M
Total Long-Term Assets $700.0K $3.035M $3.179M
Total Assets $10.50M $18.22M $13.50M
YoY Change -42.36% -20.68% -47.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $200.0K $753.0K $500.0K
YoY Change -73.44% 6.66% 25.0%
Accrued Expenses $900.0K $1.200M $2.800M
YoY Change -25.0% 71.43% 133.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.100M $1.948M $3.241M
YoY Change -43.53% 29.87% 102.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $200.0K $300.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $200.0K $300.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.100M $1.948M $3.241M
Total Long-Term Liabilities $0.00 $200.0K $300.0K
Total Liabilities $1.100M $2.184M $3.522M
YoY Change -49.63% 50.41% 120.13%
SHAREHOLDERS EQUITY
Retained Earnings -$50.55M -$46.45M
YoY Change 50.88%
Common Stock $66.58M $56.38M
YoY Change 21.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.356M $16.03M $9.929M
YoY Change
Total Liabilities & Shareholders Equity $10.50M $18.22M $13.45M
YoY Change -42.36% -20.68% -48.07%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$2.586M -$4.093M -$4.881M
YoY Change -36.82% 28.35% 73.95%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$3.020M -$4.930M -$4.023M
YoY Change -38.74% 47.6% 77.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.0K
YoY Change -98.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 9.570M 107.0K
YoY Change -100.0% -98.57%
NET CHANGE
Cash From Operating Activities -3.020M -4.930M -4.023M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 9.570M 107.0K
Net Change In Cash -3.020M 4.640M -3.916M
YoY Change -165.09% -238.92% -175.02%
FREE CASH FLOW
Cash From Operating Activities -$3.020M -$4.930M -$4.023M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 nvus Accrued Severance Current
AccruedSeveranceCurrent
490000
us-gaap Net Income Loss
NetIncomeLoss
-8974000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5286000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3678000
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
490000
us-gaap Restructuring Charges
RestructuringCharges
490000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
4089000
us-gaap Operating Expenses
OperatingExpenses
5969000
us-gaap Operating Expenses
OperatingExpenses
8964000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4089000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5969000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8964000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35000
nvus Warrant Inducement Expense
WarrantInducementExpense
4829000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2586000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4093000
us-gaap Net Income Loss
NetIncomeLoss
-10763000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17124331
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10595511
nvus Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5191000
nvus Warrants Issued During Period Inducement Expense
WarrantsIssuedDuringPeriodInducementExpense
4829000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
634000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
11745000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
197000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14492000
nvus Share Issuance At Market Value
ShareIssuanceAtMarketValue
107000
nvus Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
9569000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
838000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
16032000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9929000
CY2019Q2 nvus Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
9569000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
627000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
nvus Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
88000
nvus Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
86000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
634000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
838000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-311000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
60000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-233000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-759000
nvus Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88000
nvus Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5218000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8945000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9676000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5191000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5191000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9676000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
731000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8791000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12972000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8764000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13703000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to stock-based transactions, accruals for liabilities, operating lease liability, and other matters that affect the condensed consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the <font style="color:#000000;">condensed </font>consolidated financial statements. </p>
CY2020Q2 nvus Working Capital
WorkingCapital
8700000
CY2019Q3 nvus Closing Bid Price Per Nasdaq Listing Notification Letter
ClosingBidPricePerNASDAQListingNotificationLetter
1.00
CY2019Q3 nvus Consecutive Business Days For Closing Bid Price Of Common Stock
ConsecutiveBusinessDaysForClosingBidPriceOfCommonStock
P30D
CY2019Q3 nvus Stock Market Granted Additional Calendar Days
StockMarketGrantedAdditionalCalendarDays
P180D
CY2019Q3 nvus Closing Bid Price Of Common Stock Per Nasdaq Listing Notification Letter
ClosingBidPriceOfCommonStockPerNASDAQListingNotificationLetter
1.00
CY2019Q3 nvus Number Of Consecutive Business Days Required To Regain Compliance
NumberOfConsecutiveBusinessDaysRequiredToRegainCompliance
P10D
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On May 12, 2020, the Company’s stockholders approved and adopted an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio ranging from 1 share-for-10 shares up to a ratio of 1 share-for-30 shares, which ratio will be selected by the Company’s Board of Directors and set forth in a public announcement. Management may effect the reverse stock split at any time prior to December 31, 2020. If the Company’s stock price does not meet or exceed $1.00 per share prior to the compliance deadline, management expects to effect the reverse stock split in order to regain compliance.
nvus Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2020Q2 nvus Net Loss And Comprehensive Loss Used In Calculation Of Basic And Diluted Loss Per Share
NetLossAndComprehensiveLossUsedInCalculationOfBasicAndDilutedLossPerShare
-2586000
CY2019Q2 nvus Net Loss And Comprehensive Loss Used In Calculation Of Basic And Diluted Loss Per Share
NetLossAndComprehensiveLossUsedInCalculationOfBasicAndDilutedLossPerShare
-4093000
nvus Net Loss And Comprehensive Loss Used In Calculation Of Basic And Diluted Loss Per Share
NetLossAndComprehensiveLossUsedInCalculationOfBasicAndDilutedLossPerShare
-10763000
nvus Net Loss And Comprehensive Loss Used In Calculation Of Basic And Diluted Loss Per Share
NetLossAndComprehensiveLossUsedInCalculationOfBasicAndDilutedLossPerShare
-8974000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9481958
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8233947
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
471000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
734000
CY2020Q2 nvus Prepaid Clinical Expense
PrepaidClinicalExpense
217000
CY2019Q4 nvus Prepaid Clinical Expense
PrepaidClinicalExpense
102000
CY2020Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
64000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
45000
CY2020Q2 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
162000
CY2019Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
245000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
83000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
54000
CY2020Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
8000
CY2019Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
40000
CY2020Q2 nvus Accrued Clinical Current
AccruedClinicalCurrent
32000
CY2019Q4 nvus Accrued Clinical Current
AccruedClinicalCurrent
437000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
105000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
130000
CY2020Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
115000
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
199000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7000
CY2020Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
47000
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
47000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
93000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
95000
nvus Area Of Office Space
AreaOfOfficeSpace
5197
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-09-30
nvus Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P1Y3M
CY2020Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Operating Lease Cost
OperatingLeaseCost
98000
us-gaap Operating Lease Payments
OperatingLeasePayments
93000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0325
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
95000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
146000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
241000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
236000
nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2019Q1 nvus Milestone Payment Made
MilestonePaymentMade
300000
CY2020Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020Q2 nvus Contingent Liability
ContingentLiability
0
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7415591
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7070680
nvus Class Of Warrant Or Right Number Of Warrants Or Rights Issued
ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
7243135
nvus Class Of Warrant Or Right Number Of Warrants Or Rights Exercised
ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
6898224
nvus Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Expired
ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
0
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
197000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
627000
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
490000

Files In Submission

Name View Source Status
0001564590-20-040128-index-headers.html Edgar Link pending
0001564590-20-040128-index.html Edgar Link pending
0001564590-20-040128.txt Edgar Link pending
0001564590-20-040128-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nvus-10q_20200630.htm Edgar Link pending
nvus-20200630.xml Edgar Link completed
nvus-20200630.xsd Edgar Link pending
nvus-20200630_cal.xml Edgar Link unprocessable
nvus-20200630_def.xml Edgar Link unprocessable
nvus-20200630_lab.xml Edgar Link unprocessable
nvus-20200630_pre.xml Edgar Link unprocessable
nvus-ex311_7.htm Edgar Link pending
nvus-ex312_6.htm Edgar Link pending
nvus-ex321_8.htm Edgar Link pending
nvus-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending